Anti-diabetic combinations
AssigneeNectid Inc.
InventorRamesh Sesha
Life of this patent
Estimating the term…
Abstract
A pharmaceutical composition comprising a dipeptidyl peptidase IV inhibitor and a slow release biguanide is provided. A method for treating diabetes in a patient in need thereof including administering an anti-diabetic combination comprising a DPP inhibitor and a slow release biguanide is also provided.
Claims17
A pharmaceutical composition for treating diabetes comprising:
- a) a slow release core comprising metformin or a pharmaceutically acceptable salt thereof, and optionally one pharmaceutically acceptable excipient, and
- b) an immediate release coating comprising a dipeptidyl peptidase IV inhibitor or a pharmaceutically acceptable salt thereof.
A method for treating diabetes comprising administering to a patient in need thereof a pharmaceutical composition comprising slow release metformin or a pharmaceutically acceptable salt thereof;
- and a dipeptidyl peptidase IV inhibitor or a pharmaceutically acceptable salt thereof.
A pharmaceutical composition comprising a slow release metformin and a dipeptidyl peptidase IV inhibitor, wherein the said composition exhibits a dissolution profile such that;
- after two hours from 0 to about 25 percent of metformin is released, after four hours from about 10 to about 45 percent of metformin is released, after eight hours from about 30 to about 90 percent of metformin is released, after twelve hours not less than 50 percent of metformin is released, after sixteen hours not less than 60 percent of metformin is released, when tested in a USP type 1 apparatus, at pH 2.0 in a HCl-0.3M KCl buffer solution.
Dependencies are inferred from the claim text.